Seres Therapeutics(MCRB) - 2021 Q1 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the transition period from to Commission file number: 001-37465 Seres Therapeutics, Inc. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Washington, D.C. 20549 FORM 10-Q | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | ...